The Interplay between COVID-19 and Diabetes: Understanding Hyperglycemia, Complications, and Management Challenges in Diabetic Patients

Nambi Namusisi H.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

The COVID-19 pandemic has significantly impacted individuals with diabetes, revealing a complex interplay between the virus and pre-existing hyperglycemia. This review explores how COVID-19 exacerbates hyperglycemia in diabetic patients, primarily through mechanisms such as stress response, cytokine storms, and increased insulin resistance. Diabetic individuals are particularly susceptible to severe COVID-19 outcomes, including heightened mortality rates, due to compromised immune responses and coexisting conditions like cardiovascular and renal complications. The review also addresses the unique challenges of managing diabetes during COVID-19, including the need for adjustments in insulin therapy and the impact of COVID-19 treatments, such as corticosteroids, on glucose control. Additionally, it highlights the potential long-term effects of COVID-19 on diabetic patients, including the onset of new diabetes and persistent metabolic issues. The review emphasizes the importance of glycemic control, vaccination, and holistic care approaches to mitigate the severity of COVID-19 in diabetic patients. Furthermore, it examines the psychological and socioeconomic impacts of the pandemic on this vulnerable population. As ongoing research continues to investigate the interaction between COVID-19 and diabetes, this review provides a comprehensive understanding of the challenges and future directions in managing diabetic patients during and after the pandemic.
Keywords: COVID-19, Diabetes, Hyperglycemia, Complications, Management Challenges, Diabetic Patients

INTRODUCTION

The COVID-19 pandemic has posed significant challenges for individuals with pre-existing health conditions, particularly those with diabetes. Among diabetic patients, hyperglycemia, or elevated blood glucose levels, has emerged as a common and concerning issue during COVID-19 infection [1]. This review delves into the multifaceted relationship between diabetes and COVID-19, exploring how the infection exacerbates hyperglycemia through mechanisms such as stress response, cytokine storms, and insulin resistance. Diabetic patients are at heightened risk of severe outcomes, including increased mortality rates, due to the compounded effects of uncontrolled diabetes and the virus's impact on the immune system. The immune response in diabetic individuals is often compromised, leading to a higher susceptibility to secondary infections and more severe COVID-19 complications. Furthermore, the pandemic has introduced unique management challenges, requiring adjustments in insulin therapy, oral hypoglycemic agents, and careful consideration of the effects of COVID-19 treatments like corticosteroids on diabetes control [2]. Beyond the acute phase of infection, the potential for long-term effects, including the onset of new diabetes and persistent metabolic complications, underscores the need for ongoing monitoring and research. This review also highlights preventive strategies, such as the importance of glycemic control and vaccination, to reduce the severity of COVID-19 in diabetic patients. Additionally, it addresses the psychological and socioeconomic impacts of the pandemic on this vulnerable population, emphasizing the need for holistic care approaches [3]. As researchers continue to investigate the interaction between COVID-19 and

diabetes, this review aims to provide a comprehensive understanding of the challenges and future directions in managing diabetic patients during and after the pandemic.

Impact on Blood Glucose Levels

Hyperglycemia, or high blood glucose levels, is a common issue in diabetic patients infected with COVID-19. The infection can lead to acute hyperglycemia due to several factors, including direct viral impact, stress response, and cytokine storm [4]. Stress hormones like cortisol and adrenaline increase blood glucose levels, especially in individuals with pre-existing diabetes. The inflammatory response triggers elevated levels of cytokines and other inflammatory markers, which interfere with insulin signaling pathways, making it harder for cells to utilize glucose effectively. Hormonal changes, such as cortisol release, promote gluconeogenesis, which can increase blood glucose levels by promoting gluconeogenesis and decreasing insulin effectiveness. The autonomic nervous system is activated, leading to increased glucose production and decreased insulin sensitivity. Insulin resistance, a condition where cells do not respond effectively to insulin, is often worsened during COVID-19. Inflammatory mediators, such as corticosteroids, can exacerbate insulin resistance. The viral impact on insulin pathways may further worsen the body's ability to use insulin effectively, leading to higher blood glucose levels and complicating diabetes management [5].

COVID-19 Severity and Diabetes

Diabetes patients are at a higher risk of severe outcomes when infected with COVID-19 due to several factors [6]. Poorly controlled diabetes weakens the immune system, making it harder for the body to fight off infections like COVID-19. Chronic inflammation, exacerbated by COVID-19, leads to a more severe inflammatory response known as a cytokine storm. Coexisting conditions, such as hypertension, cardiovascular disease, and obesity, complicate the management of COVID-19 and increase the risk of severe complications and death. Uncontrolled diabetes is linked to higher mortality rates in COVID-19 patients. High blood glucose levels, a hallmark of uncontrolled diabetes, are associated with an increased risk of death in COVID-19 patients. Impaired healing and recovery from infections, prolonged hospital stays, increased use of mechanical ventilation, and higher mortality rates are also linked to poor glucose control. Diabetic patients with COVID-19 are more likely to require hospitalization and intensive care due to the complexity of managing both conditions. High hospitalization rates are driven by the severity of symptoms, comorbidities, and the challenges of managing diabetes alongside an acute viral infection [7]. During hospitalization, diabetic patients are at higher risk of complications, including acute kidney injury, heart failure, and thromboembolic events, which may require intensive care.

Immune Response and Diabetes

Diabetes significantly alters the immune response, making it harder for the body to defend against infections like COVID-19. This includes impaired innate immunity, dysfunctional adaptive immunity, and delayed viral clearance [8]. Chronic inflammation and the potential for a cytokine storm are critical factors in the severity of COVID-19 in diabetic patients. Chronic inflammation, characterized by elevated levels of pro-inflammatory cytokines, can weaken the immune system over time and contribute to tissue damage. When a diabetic patient contracts COVID-19, the already elevated inflammatory state can be exacerbated, leading to an overwhelming immune response known as a cytokine storm. This can cause widespread tissue damage, organ failure, and severe complications [9]. Diabetic patients with COVID-19 are particularly vulnerable to secondary infections, which can further complicate their recovery. High blood sugar levels can further weaken the immune system, leading to increased risk of infections like bacterial pneumonia. Hospital-acquired infections, such as ventilator-associated pneumonia and catheter-associated urinary tract infections, can prolong hospitalization, complicate treatment, and increase the risk of mortality. Understanding these factors is crucial for managing diabetic patients with COVID-19 and reducing their risk of severe complications [10].

Complications and Comorbidities

Diabetes patients with COVID-19 are at a higher risk of developing cardiovascular complications due to the interplay between diabetes, the virus, and pre-existing cardiovascular conditions [11]. These conditions, such as hypertension, coronary artery disease, and heart failure, can increase the risk of acute cardiovascular events. COVID-19 can trigger a severe inflammatory response, leading to widespread inflammation of blood vessels and increased risk of clot formation. The increased metabolic demands and stress placed on the cardiovascular system during a COVID-19 infection can exacerbate underlying heart conditions, further complicating the clinical course. COVID-19 can have a profound impact on kidney function, particularly in diabetic patients who are already at risk for renal complications. Pre-existing diabetic nephropathy makes the kidneys more vulnerable to additional stressors, such as the systemic effects of COVID-19. COVID-19-associated acute kidney injury (AKI) can lead to sudden loss of kidney function, exacerbated by hyperglycemia and chronic inflammation. AKI in diabetic patients with COVID-19 is associated with a higher risk of mortality, making management challenging [12]. Respiratory

complications are a major concern for diabetic patients with COVID-19, making them more susceptible to severe respiratory infections, including pneumonia and acute respiratory distress syndrome (ARDS). Mechanical ventilation is often necessary to support breathing, but it is associated with a higher risk of complications and increased mortality.

Management Challenges

Long-Term Managing diabetes during COVID-19 treatment presents unique challenges, including hyperglycemia and variability, acute illness impact, limited monitoring, and adjustments in insulin therapy and oral hypoglycemic agents [13]. Hyperglycemia can impair immune function, increase the risk of infections, and worsen outcomes. The acute illness phase can exacerbate blood glucose variability, leading to episodes of both hyperglycemia and hypoglycemia. Oral hypoglycemic agents may need to be reconsidered due to increased insulin resistance, stress-induced hyperglycemia, or changes in dietary intake. Patients on oral hypoglycemic agents may be switched to insulin therapy to achieve better glycemic control. Corticosteroids, commonly used in severe COVID-19 treatment, can significantly raise blood glucose levels, leading to steroid-induced hyperglycemia. Patients receiving corticosteroids may need higher doses of insulin to counteract the hyperglycemic effects. Steroid-induced hyperglycemia can increase the risk of complications such as infections, poor wound healing, and hyperosmolar hyperglycemic state [14]. Antiviral drugs, immunomodulators, and treatments used in COVID-19 management can interact with diabetes medications or affect glucose metabolism. Fluid management in hospitalized patients can impact glucose control, particularly if dextrose-containing solutions are used. Managing diabetes during COVID-19 requires careful consideration of the virus, treatment regimen, and medications used. Healthcare providers must be vigilant in monitoring and adjusting diabetes management strategies to ensure optimal glycemic control and minimize the risk of complications [15].

Effects

Long COVID, or Long COVID, is a condition characterized by persistent symptoms that persist for weeks or months after the acute phase of a COVID-19 infection has resolved. This can worsen existing diabetes by perpetuating insulin resistance and making blood glucose control more challenging. Chronic inflammation, neurological and psychological impacts, and increased cardiovascular risk can also be experienced [16]. New-onset diabetes may be triggered by virus-induced damage to pancreatic beta cells, impaired insulin secretion, and immune-mediated mechanisms. The use of corticosteroids during COVID-19 treatment may unmask a predisposition to diabetes, leading to the development of diabetes even after steroids are discontinued. Long-term metabolic and vascular effects of COVID-19 can lead to chronic hyperglycemia, vascular damage, thrombosis, and renal complications. These effects extend beyond the acute phase of the illness, requiring ongoing monitoring and a proactive approach to manage these patients. Managing these patients requires ongoing monitoring and a proactive approach to mitigate these risks.

Preventive Strategies

During the COVID-19 pandemic, diabetic patients are at higher risk of severe illness and complications due to their high blood glucose levels. Proper glycemic control can reduce the likelihood of complications such as hyperinflammatory responses and cytokine storms. Poor glycemic control can impair the immune response, making diabetic individuals more susceptible to infections [17]. Well-controlled blood sugar levels have a lower risk of hospitalization and ICU admission compared to poorly managed diabetes. Vaccination is particularly important for diabetic patients, as it reduces the risk of severe disease, hospitalization, and death. However, some diabetic patients may experience short-term fluctuations in blood glucose levels following vaccination, so it is important to monitor their blood sugar closely and adjust their medication as needed. Boosters and additional doses of the vaccine are often recommended to maintain strong immunity over time. Living and exercising are essential for managing diabetes during the pandemic, as they help control blood glucose levels [18]. Telemedicine has become an invaluable tool during the pandemic, allowing diabetic patients to access healthcare services without the risk of exposure to COVID-19. Home monitoring devices, such as continuous glucose monitors and blood pressure monitors, allow diabetic patients to track their health metrics in real-time and stay connected with their healthcare team. Preventive strategies for diabetic patients during the COVID-19 pandemic emphasize the importance of glycemic control, vaccination benefits, lifestyle modifications, and telemedicine.

Psychological Impact

The COVID-19 pandemic has significantly heightened the psychological burden on diabetic patients, who are already coping with the stress of managing a chronic illness. The fear of contracting the virus and the potential for severe complications can exacerbate feelings of anxiety, stress, and uncertainty [19]. The pandemic has disrupted access to in-person mental health services, making it more challenging for diabetic patients to seek counseling or therapy. Health-related anxiety and depression are common among diabetic patients, especially those who need to

leave home for work, medical appointments, or essential activities. Depressive symptoms are also increased due to fears of illness, future concerns, and the challenges of managing diabetes in a rapidly changing healthcare environment. Coping with uncertainty about the pandemic, vaccine effectiveness, and the potential for new variants can contribute to ongoing anxiety and depression in diabetic patients. Isolation and reduced physical activity have further complicated diabetes management, as lockdowns, gym closures, and restrictions on outdoor activities have led to a reduction in physical activity for many people, including those with diabetes. Emotional eating and dietary challenges may also arise due to stress, boredom, and emotional distress during the pandemic [20]. The disruption of routine and limited access to healthy food options can make it challenging to maintain a balanced diet. Th3 psychological impact of COVID-19 on diabetic patients includes significant mental health challenges, including increased anxiety and depression related to the risk of severe illness.

Socioeconomic Factors

The COVID-19 pandemic has exacerbated existing healthcare disparities, particularly for diabetic patients from low-income, minority, or rural communities. These patients face barriers such as limited access to healthcare facilities, lack of insurance coverage, and transportation challenges [21]. The shift to telemedicine has exposed a digital divide, as diabetic patients without reliable internet access struggle to participate in virtual consultations or access online health resources. Language and cultural barriers also affect diabetic patients from non-English speaking backgrounds, leading to misunderstandings and suboptimal care. Economic challenges, such as job loss, reduced income, and financial instability, have made it difficult for diabetic patients to afford essential supplies, medications, or healthy food. Economic hardship also limits access to healthy, diabetes-friendly foods, exacerbated blood glucose fluctuations, and increased the risk of diabetes-related complications [22]. Disruptions in routine healthcare services, deferred preventive care, and overburdened healthcare systems have made it difficult for diabetic patients to receive timely care.

Research and Future Directions

The ongoing research on COVID-19 and diabetes is focusing on understanding the complex relationship between the virus and diabetes, aiming to determine why diabetic patients are more susceptible to severe COVID-19, how the virus influences blood glucose levels, and the long-term effects on diabetes progression [23]. Researchers are investigating biomarkers and predictors to predict severe outcomes in diabetic patients, and examining the role of inflammatory markers in predicting the course of COVID-19 in diabetic patients. Large-scale data collection and registries are being developed to track the health outcomes of diabetic patients infected with COVID-19, guiding public health responses. Targeted therapies, personalized medicine, and adjunctive treatments are being developed to address the specific needs of diabetic patients. Future research priorities include longitudinal studies to follow diabetic patients who have recovered from COVID-19, mechanistic studies to unravel the biological processes underlying the interaction between COVID-19 and diabetes, public health and policy research to assess the effectiveness of vaccination programs, and global and regional studies to consider regional and global variations in the virus's impact on diabetic populations [24].

CONCLUSION

The interplay between COVID-19 and diabetes has unveiled a complex and multifaceted relationship, where hyperglycemia exacerbates the severity of the infection, leading to a range of complications and management challenges. Diabetic patients are particularly vulnerable to the detrimental effects of COVID-19, with compromised immune responses, increased risks of cardiovascular and renal complications, and the potential for long-term metabolic consequences. The pandemic has highlighted the critical importance of glycemic control, not only as a preventive measure but also as a key factor in improving outcomes for diabetic patients. Management of diabetes during COVID-19 has required careful adjustments in therapeutic strategies, particularly in response to the effects of COVID-19 treatments like corticosteroids. The challenges of maintaining optimal blood glucose levels amidst acute illness and the introduction of new-onset diabetes in some patients underscore the need for individualized care plans. Moreover, the psychological and socioeconomic impacts of the pandemic on diabetic patients emphasize the necessity of a holistic approach to care that addresses both physical and mental health needs. As we continue to navigate the pandemic and its aftermath, ongoing research is crucial to deepen our understanding of the biological mechanisms underlying the interaction between COVID-19 and diabetes. Future studies should focus on developing targeted therapies and public health strategies that can mitigate the impact of COVID-19 on diabetic populations, particularly in vulnerable communities. The integration of innovative technologies, such as telemedicine and home monitoring, will play a vital role in enhancing diabetes management and reducing the burden on healthcare systems. Therefore, the COVID-19 pandemic has underscored the need for comprehensive and adaptive approaches to managing diabetes, particularly in the face of emerging infectious diseases. By prioritizing glycemic control, advancing research, and addressing the broader social determinants of

health, we can better protect diabetic patients and improve their outcomes during this and future public health crises.

REFERENCES

1. Obeagu, E. I., Scott, G. Y., Amekpor, F., Ugwu, O. P. C., Alum, E. U. COVID-19 infection and Diabetes: A Current Issue. *International Journal of Innovative and Applied Research.* 2023; **11**(01): 25-30. DOI: 10.58538/IJIAR/2007. DOI URL: http://dx.doi.org/10.58538/IJIAR/2007.
2. Zhang, X., Wang, Y., Chen, Z., Hu, Q., Zhao, C., & Han, Y. (2024). Hyperglycemia and COVID-19: The Impact on Diabetic Complications and Glycemic Management. *Diabetes Care, 47*(1), 56-64. doi:10.2337/dc23-0987.
3. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long Term Implications of Gestational Diabetes Mellitus.*INOSR Scientific Research.* 2024; 11(1):63-71.https://doi.org/10.59298/INOSRSR/2024/1.1.16371
4. Pal, R., Bhansali, A., & Aggarwal, S. (2023). Understanding the Bidirectional Relationship between COVID-19 and Diabetes: Mechanisms and Management Strategies. *The Lancet Diabetes & Endocrinology, 11*(3), 210-219. doi:10.1016/S2213-8587(23)00107-5.
5. Ceriello, A., De Nigris, V., & Prattichizzo, F. (2023). Hyperglycemia in COVID-19: A Determinant of Poor Prognosis. *Diabetes Research and Clinical Practice, 196*, 109835. doi:10.1016/j.diabres.2023.109835.
6. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences.2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
7. Guo, W., Li, M., Dong, Y., Zhou, X., Zhang, Z., Tian, C., ... & Yan, L. (2023). Mechanistic Insights into Hyperglycemia-Induced Exacerbation of COVID-19 in Diabetic Patients. *Journal of Molecular Medicine, 102*(7), 987-995. doi:10.1007/s00109-023-02293-1.
8. Aja, P. M., Igwenyi, I. O., Ugwu, O. P. C., Orji, O. U., Alum, E. U. Evaluation of Anti-diabetic Effect and Liver Function Indices of Ethanol Extracts of *Moringaoleifera* and *Cajanuscajan* Leaves in Alloxan Induced Diabetic Albino Rats. *Global Veterinaria.* 2015;14(3): 439-447. DOI: 10.5829/idosi.gv.2015.14.03.93129.
9. Wang, S., Ma, Q., Ren, J., & Zhang, Z. (2024). COVID-19-Associated Hyperglycemia and Its Management in Diabetic Patients. *Journal of Diabetes and Its Complications, 38*(2), 107425. doi:10.1016/j.jdiacomp.2023.107425.
10. Yadav, R., & Jha, N. K. (2023). The Impact of COVID-19 on Diabetic Patients: Hyperglycemia, Immune Response, and Management Challenges. *Frontiers in Endocrinology, 14*, 1053723. doi:10.3389/fendo.2023.1053723.
11. Chen, Y., Tian, Y., Tang, X., & Wang, L. (2023). COVID-19 and Diabetes: The Role of Hyperglycemia in Immune Dysfunction and Severe Outcomes. *Endocrine Reviews, 44*(1), 35-56. doi:10.1210/endrev/bnad021.
12. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Ugwu, C. N., Okon, M.B. Nutritional Care in Diabetes Mellitus: A Comprehensive Guide.*International Journal of Innovative and Applied Research.* 2023; 11(12):16-25.Article DOI: 10.58538/IJIAR/2057 DOI URL: http://dx.doi.org/10.58538/IJIAR/2057.
13. Singh, A. K., Gupta, R., & Misra, A. (2024). Management of Diabetes and Hyperglycemia in COVID-19 Patients: Clinical Insights and Recommendations. *Current Diabetes Reports, 24*(2), 121-130. doi:10.1007/s11892-023-01561-2.
14. Moradi, N., Rahimi, M., & Zandi, N. (2024). The Role of Insulin Resistance in COVID-19-Associated Hyperglycemia: Implications for Management in Diabetic Patients. *Journal of Clinical Endocrinology & Metabolism, 109*(1), e89-e98. doi:10.1210/clinem/dgad520.
15. Tripathi, R., Tiwari, R., & Khan, A. (2023). The Intersection of COVID-19 and Diabetes: Challenges in Managing Hyperglycemia and Complications. *Diabetes Therapy, 14*(7), 1693-1706. doi:10.1007/s13300-023-01495-9.
16. Obeagu, E. I., Ugwu, O. P. C., Alum, E. U. Poor glycaemic control among diabetic patients; A review on associated factors. *Newport International Journal of Research in Medical Sciences (NIJRMS).* 2023; 3(1):30-33. https://nijournals.org/newport-international-journal-of-research-in-medical-sciences-nijrms-volume-3-issue-1-2023/.
17. Aja, P. M., Ani, O. G., Offor, C. E., Orji, U. O., Alum, E. U. Evaluation of Anti-Diabetic Effect and Liver Enzymes Activity of Ethanol Extract of *Pterocarpussantalinoides* in Alloxan Induced Diabetic Albino Rats.

Global Journal of Biotechnology & Biochemistry. 2015;10 (2): 77-83. DOI: 10.5829/idosi.gjbb.2015.10.02.93128.

18. Ugwu, O. P.C., Alum, E. U., Obeagu, E. I, Okon, M. B., Aja, P. M., Samson, A. O., Amusa, M. O. and Adepoju, A. O. Effect of Ethanol Leaf extract of *Chromolaenaodorata* on hepatic markers in streptozotocin-induced diabetic wistar albino rats. *IAA Journal of Applied Sciences,* 2023; 9(1):46-56. https://doi.org/10.5281/zenodo.7811625

19. Egwu, C. O., Offor, C. E. and Alum, E. U. Anti-diabetic effects of *Buchholziacoriacea* ethanol seed Extract and Vildagliptin on Alloxan-induced diabetic albino Rats. *International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS).* 2017; 6 (6): 1304-1314. www.ijbpas.com. https://ijbpas.com/pdf/2017/June/1497506120MS%20IJBPAS%202017%204202.pdf

20. Ugwu O, P, C., Alum, E, U., Obeagu, E, I., Okon, M, B., Aja, P, M., Samson, A, O., Amusa, M, O., Adepoju, A, O. Effect of Ethanol leaf extract of Chromolaenaodorata on lipid profile of streptozotocin induced diabetic wistar albino rats.*IAA Journal of Biological Sciences.* 2023;10(1):109-117. https://www.iaajournals.org/wp-content/uploads/2023/03/IAAJB-101109-117-2023-Effect-of-Ethanol-leaf-extract-of-Chromolaena-odorata-on-lipid-profile-of-streptozotocin-induced-diabetic-wistar-albino-rats..docx.pdf.

21. Ezeani, N, N., Edwin, N., Alum, E, U., Orji, O, U, Ugwu, O, P, C., Effect of Ethanol Leaf Extract of *Ocimumgratissmum* (Scent Leaf) on Lipid Profile of Alloxan-Induced Diabetic Rats. *International Digital Organization for Scientific Research Journal of Experimental Sciences,* 2017; 2 (1): 164-179. www.idosr.org. https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JES-21-164-179-2017.-ezeani-2-updated.pdf

22. Ezeani, N, N., Alum, E, U., Orji, O, U., Edwin, N. The Effect of Ethanol Leaf Extract of *Pterocarpus santalinoids* (Ntrukpa) on the Lipid Profile of Alloxan-Induced Diabetic Albino Rats. *International Digital Organization for Scientific Research Journal of Scientific Research.* 2017; 2 (2): 175-189. www.idosr.org. https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JSR-22-175-189-2017-EZEANI-updated.pdf

23. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long Term Implications of Gestational Diabetes Mellitus.*INOSR Scientific Research.* 2024; 11(1):63-71.https://doi.org/10.59298/INOSRSR/2024/1.1.16371

24. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. (2024). Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. Research Invention Journal of Research in Medical Sciences. 3(2):38-49.